Rohto Pharmaceutical Co.,Ltd. (TYO:4527)

Rohto Pharmaceutical Ratios and Metrics

Market cap in millions JPY. Fiscal year is April - March.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 20, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Market Capitalization	653,828	544,009	505,369	676,888	631,946	421,488
Market Cap Growth	17.98%	7.65%	-25.34%	7.11%	49.93%	25.13%
Enterprise Value	646,128	539,100	493,570	610,616	575,682	380,505
Last Close Price	2893.50	2386.07	2175.57	2848.52	2638.55	1744.08

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 20, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	20.59	15.89	16.30	21.88	23.96	20.05
Forward PE	17.57	16.34	15.19	20.08	24.15	19.94
PS Ratio	1.85	1.58	1.64	2.50	2.65	2.11
PB Ratio	1.99	1.70	1.86	2.74	2.94	2.29
P/TBV Ratio	2.90	2.50	2.48	2.86	3.16	2.49
P/FCF Ratio	18.01	14.99	18.16	25.77	28.15	24.82
P/OCF Ratio	13.68	11.38	13.69	19.77	20.43	15.47
PEG Ratio	2.65	4.54	2.03	1.63	4.00	4.00

EV Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 20, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
EV/Sales Ratio	1.83	1.57	1.60	2.26	2.41	1.91
EV/EBITDA Ratio	10.48	9.28	9.56	12.50	13.93	10.61
EV/EBIT Ratio	14.96	13.24	12.83	15.20	17.17	13.50
EV/FCF Ratio	17.80	14.85	17.73	23.25	25.64	22.41

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 20, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Debt / Equity Ratio	0.18	0.19	0.19	0.04	0.05	0.12
Debt / EBITDA Ratio	0.95	1.04	0.97	0.21	0.28	0.60
Debt / FCF Ratio	-	1.66	1.80	0.40	0.52	1.26
Net Debt / Equity Ratio	-0.08	-0.08	-0.10	-0.32	-0.32	-0.28
Net Debt / EBITDA Ratio	-0.44	-0.46	-0.52	-1.61	-1.65	-1.43
Net Debt / FCF Ratio	-	-0.73	-0.97	-3.00	-3.04	-3.03
Asset Turnover	0.77	0.76	0.80	0.83	0.82	0.80
Inventory Turnover	2.37	2.37	2.47	2.59	2.72	2.71
Quick Ratio	1.44	1.40	1.55	1.82	1.75	1.74
Current Ratio	2.17	2.04	2.30	2.47	2.37	2.30
Return on Equity (ROE)	10.91%	11.63%	11.94%	13.59%	13.25%	12.42%
Return on Assets (ROA)	5.82%	5.61%	6.26%	7.66%	7.17%	7.04%
Return on Invested Capital (ROIC)	10.28%	11.12%	13.63%	19.28%	18.52%	17.47%
Return on Capital Employed (ROCE)	11.30%	11.00%	11.80%	15.50%	14.60%	13.90%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct 20, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Earnings Yield	4.86%	6.30%	6.13%	4.57%	4.17%	4.99%
FCF Yield	5.55%	6.67%	5.51%	3.88%	3.55%	4.03%
Dividend Yield	1.73%	1.91%	1.61%	0.91%	0.79%	0.97%
Payout Ratio	35.58%	27.05%	22.81%	17.70%	17.73%	16.28%
Buyback Yield / Dilution	-2.84%	-2.87%	-0.04%	0.00%	0.00%	-
Total Shareholder Return	-1.11%	-0.96%	1.57%	0.91%	0.80%	0.97%

Data Source: S&P Global Market Intelligence Last updated: Aug 6, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 17, 2026

Data Sources Report a data error